Cart
sales@molnova.com
Vaxfectin
CAS No. 370108-99-9
Vaxfectin( —— )
Catalog No. M36593 CAS No. 370108-99-9
Vaxfectin is a lipid adjuvant used in the development of protein and peptide vaccines.Vaxfectin promotes vaccine immunogenicity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 759 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVaxfectin
-
NoteResearch use only, not for human use.
-
Brief DescriptionVaxfectin is a lipid adjuvant used in the development of protein and peptide vaccines.Vaxfectin promotes vaccine immunogenicity.
-
DescriptionVaxfectin is a cationic lipid-based adjuvant that can be used for plasmid DNA- and protein-based vaccines.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorLiposome
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number370108-99-9
-
Formula Weight1450.05
-
Molecular FormulaC81H163BrN3O10P
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[C@H](COP(OCCN)(=O)O)(COC(CC(CCCC(CCCC(CCCC(C)C)C)C)C)=O)OC(CC(CCCC(CCCC(CCCC(C)C)C)C)C)=O.C(COCCCCCCCC/C=C\CCCC)(OCCCCCCCC/C=C\CCCC)C[N+](CCCN)(C)C.[Br-]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sullivan SM, et, al. Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin Drug Deliv. 2010 Dec;7(12):1433-46.?
molnova catalog
related products
-
16,17-Didehydroganod...
3,11,15,23-Tetraoxo-27ξ-lanosta-8,16-dien-26-oic acid, a lanostane-type triterpenoid, is isolated from Antrodia camphorate.
-
FKBP12 PROTAC RC32
FKBP12 PROTAC RC32 is a PROTAC-like degrader targeting FKBP12. It can degrade FKBP12 in organs after intraperitoneal administration.
-
β-CGRP, human TFA
β-CGRP,human tissue is one of the calcitonin peptide, through complex behavior of calcitonin receptor like receptor (CRLR) - and receptor activity - modifying proteins (increased), and 1 and 300 - nM CRLR IC50s/RAMP1 and CRLR/RAMP2 cells.
